Orforglipron vs Adipotide
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronFat Loss & Metabolic
Adipotide- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Adipotide (FTPP) is a chimeric proapoptotic peptide that selectively targets and destroys blood vessels feeding white adipose tissue. It binds prohibitin on the vasculature of fat tissue, delivering a proapoptotic sequence that induces cell death in fat-specific blood vessels, causing targeted fat tissue regression.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Estimated 2-4 hours
- Admin Route
- Oral
- Subcutaneous, Intravenous (research)
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- Not established for humans; primate studies used 0.1-1 mg/kg
- Frequency
- Once daily
- Daily for 4 weeks (research protocol)
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Targeted reduction of white adipose tissue
- Promotes fat vasculature apoptosis without systemic toxicity
- Demonstrated significant fat loss in primate studies
- Potential for visceral and subcutaneous fat reduction
- Novel non-hormonal mechanism distinct from GLP-1 agonists
- Explored for obesity and metabolic syndrome
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Renal toxicity observed in primate studies (transient, dose-dependent)
- Dehydration and electrolyte imbalances in research
- Weight regain upon cessation
- Limited human data; side effect profile largely from animal studies
- Stacks With
- —
- —